Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 130

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 8
Chunk 130
---
Restructuring and restructuring-related net charges (credits)46 6 40 — 40 0.03 Investment portfolio net losses (gains) and impairments(14)(3)(11)— (11)(0.01)EU MDR implementation costs14 2 12 — 12 0.01 Deferred tax expenses (benefits)— (37)37 — 37 0.02 Adjusted$932 $99 $833 $1 $832 $0.56 

34

Quarterly Results and Business Overview 

The following section describes our net sales and results of operations by reportable segment and business. For additional information on our businesses and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. 

 Three Months Ended March 31,(in millions)20252024Increase/(Decrease)Endoscopy$673 $642 4.7%Urology633 513 23.5%Neuromodulation271 256 5.8%MedSurg1,577 1,412 11.7%Cardiology2,429 1,872 29.8%Peripheral Interventions656 573 14.4%Cardiovascular3,085 2,445 26.2%Net Sales$4,663 $3,856 20.9%

MedSurg

Endoscopy 

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions with innovative, less-invasive technologies. Net sales of Endoscopy products of $673 million during the first quarter of 2025 represented 14 percent of our consolidated net sales. Endoscopy net sales increased $30 million, or 4.7 percent, during the first quarter of 2025, compared to the prior year period. During the first quarter of 2025, this increase included operational net sales growth of 5.9 percent and the negative impact of 120 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth during the first quarter of 2025 included organic net sales growth of 5.5 percent and the positive impact of 40 basis points from our acquisition of the endoluminal vacuum therapy portfolio of Braun during the first quarter of 2024.

Organic net sales growth was primarily driven by our biliary franchise led by our